ViiV Culture=Backstabbing

Discussion in 'GlaxoSmithKline' started by anonymous, Aug 6, 2018 at 12:04 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ViiV is going to 4 reps per pod for metrics.
     

  2. anonymous

    anonymous Guest

    Yes. Could care less nobody is or will write 2DR. Let’s add more reps that no one will see.
     
  3. anonymous

    anonymous Guest

    Denver meeting, rah rah, and now more RSD spreadsheets and weekly calls.
    Triumeq isn’t important as it is a 3DR. We are 2DR. Have at it Biktarvy!
     
  4. anonymous

    anonymous Guest

    It’s like Halloween everyday in my territory watching how quickly my Triumeq is switching to Biktarvy.....scary
     
  5. anonymous

    anonymous Guest

    Ha- So true. At this pace we won’t have any presence in this space in a year or two.
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    Layoffs early 2019, right sizing HIV like rest of GSK. COCO!
     
  8. anonymous

    anonymous Guest

    This post looks correct. I think we will make it through 2018!
     
  9. anonymous

    anonymous Guest

    +1 fellow TAMS. Let’s have 3 of us make one extra call per day to further annoy customers. Leadership guarantees we will grow Juluca that way. The 90s called and wants the reach/frequency back. ViiV used to be a great place before the GSKers.
     
  10. anonymous

    anonymous Guest

    Yes. How can’t we grow this shit drug we call Juluca. I can’t wait until April, when we have another piece of crap in our bag. Insanity is defined by doing the same thing over and over, and expecting different results. Are we trying to give all our business to Biktarvy?
     
  11. anonymous

    anonymous Guest

    right on, sister. C’mon with this 2 drug bullshit already.
     
  12. anonymous

    anonymous Guest

    If you want a 3 rating, better “make” that extra call per day and edetail capture. Real deal according to my RSD.
     
  13. anonymous

    anonymous Guest

    I’m afraid the ride is over. VIIV is slowly exiting the HIV space. Nobody is buying the 2 drug push, we lost!
     
  14. anonymous

    anonymous Guest

    We lost by walking away from Triumeq and 3DR standard of care. Gilead should thank us.
     
  15. anonymous

    anonymous Guest

    I 100% agree! We have made ourselves a niche company with niche products.
     
  16. decade501

    decade501 New Member

    Joined:
    Nov 18, 2018
    Messages:
    11
    Likes Received:
    0
    Have fun on a sinking ship while us vaccine boys get a 200% bonus
     
  17. anonymous

    anonymous Guest

    I left but check in to see the gosip once in a while; this post struck me because of all the vast universe of stupidity that is ViiV, it was the electronic leash that made me most feel like a useless piece of shit. It was so freaking demeaning to have to carry around an ipad and enter all that false reporting every day. I love my new job and have NONE of that e-detailing-track-me-like-a-criminal horse shit. Life is better outstide of ViiV/GSK. Every time I see one of those dumb GSK commercials on tv with the heartbeat at the end it reminds me what a miserable experience my short tenure there was. Get out and experience job satisfaction.
     
  18. anonymous

    anonymous Guest

    With the way we are headed with these ridiculous 2 drug combo drugs, we won’t need to get out. ViiV won’t be in the HIV space much longer, it’s over
     
  19. anonymous

    anonymous Guest

    Unfortunately since we aren’t paid or rated on sales, to get a 3 or higher got to have high edetail usage and a bunch of false calls on docs we can’t see. What is pathetic is that we are supposed to be account managers. The problem isn’t us it is the 2DR or die strategy. Time to go make more edetails for the RSD
     
  20. anonymous

    anonymous Guest

    Exactly. I hardly see anyone I claim to see, and when I do they laugh me out of their office when I try to get them to use 2DR.